Skip to main content

VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls

Breast Cancer Research and Treatment volume 125, pages 489–493 (2011)Cite this article

Abstract

Vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens and plays an important role in angiogenesis. Many published studies have evaluated the association between the VEGF 936C>T polymorphism and breast cancer risk. However, the published findings are inconsistent. In order to derive a more precise estimation of the association, a meta-analysis was performed in this study. A total of eight studies including 5,729 breast cancer cases and 5,868 controls were identified. Overall, no significant associations between the VEGF 936C>T polymorphism and breast cancer risk were found for TT versus CC (OR 0.93, 95% CI 0.73–1.19), CT versus CC (OR 0.91, 95% CI 0.77–1.09), TT/CT versus CC (OR 0.92, 95% CI 0.78–1.08), and TT versus CT/CC (OR 0.96, 95% CI 0.75–1.21). In the subgroup analysis by ethnicity, source of controls, and menopausal status, there was still no significant association detected in any of the genetic models. In summary, our results suggest that the VEGF 936C>T polymorphism may not contribute to breast cancer susceptibility.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168–183

    Article  PubMed  Google Scholar 

  2. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    CAS  Article  PubMed  Google Scholar 

  3. Schneider BP, Miller KD (2005) Angiogenesis of breast cancer. J Clin Oncol 23:1782–1790

    CAS  Article  PubMed  Google Scholar 

  4. Schneider BP, Sledge GW Jr (2007) Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4:181–189

    CAS  Article  PubMed  Google Scholar 

  5. Ferrara N, Gerber HP (2001) The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 106:148–156

    CAS  Article  PubMed  Google Scholar 

  6. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56:2013–2016

    CAS  PubMed  Google Scholar 

  7. Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16:3121–3128

    CAS  PubMed  Google Scholar 

  8. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245–1249

    CAS  Article  PubMed  Google Scholar 

  9. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954

    CAS  PubMed  Google Scholar 

  10. Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48:563–569

    CAS  Article  PubMed  Google Scholar 

  11. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448

    CAS  Article  PubMed  Google Scholar 

  12. Wolf G, Aigner RM, Schaffler G, Langsenlehner U, Renner W, Samonigg H, Yazdani-Biuki B, Krippl P (2004) The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake. Breast Cancer Res Treat 88:205–208

    CAS  Article  PubMed  Google Scholar 

  13. Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, Edler L, Lubinski J, Scott RJ, Hamann U (2007) The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262:71–76

    Article  Google Scholar 

  14. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471

    CAS  Article  PubMed  Google Scholar 

  15. Jakubowska A, Jaworska K, Cybulski C, Janicka A, Szymanska-Pasternak J, Lener M, Narod SA, Lubinski J (2009) Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer 45:837–842

    CAS  Article  PubMed  Google Scholar 

  16. Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, Wascher TC, Paulweber B, Samonigg H, Krippl P et al (2008) Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat 109:297–304

    CAS  Article  PubMed  Google Scholar 

  17. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653

    CAS  Article  PubMed  Google Scholar 

  18. Handoll HH (2006) Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil 87:875

    Article  PubMed  Google Scholar 

  19. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    CAS  PubMed  Google Scholar 

  20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    CAS  Article  PubMed  Google Scholar 

  21. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    CAS  PubMed  Google Scholar 

  22. Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15:1148–1152

    CAS  Article  PubMed  Google Scholar 

  23. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8:R22

    Article  PubMed  Google Scholar 

  24. Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ, Reed MW (2007) Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 121:1009–1016

    CAS  Article  PubMed  Google Scholar 

  25. Eroglu A, Ozturk A, Cam R, Akar N (2008) Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients. Med Oncol 25:54–55

    CAS  Article  PubMed  Google Scholar 

  26. Lin GT, Tseng HF, Yang CH, Hou MF, Chuang LY, Tai HT, Tai MH, Cheng YH, Wen CH, Liu CS et al (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 13:165–172

    CAS  Article  PubMed  Google Scholar 

  27. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Helena Chang (University of Wisconsin School of Medicine and Public Health) for scientific editing.

Author information

Affiliations

  1. Department of Molecular and Genetic Toxicology, School of Public Health, Nanjing Medical University, 140 Hanzhong Road, Nanjing, 210029, People’s Republic of China

    Dongying Gu & Meilin Wang

  2. Department of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, People’s Republic of China

    Dongying Gu

Authors
  1. Dongying Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meilin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meilin Wang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gu, D., Wang, M. VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls. Breast Cancer Res Treat 125, 489–493 (2011). https://doi.org/10.1007/s10549-010-0991-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-0991-z

Keywords

  • VEGF
  • Breast cancer
  • Meta-analysis
  • Molecular epidemiology